Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Non-Current Debt (2016 - 2024)

Historic Non-Current Debt for Sanofi (SNY) over the last 17 years, with Q2 2025 value amounting to $14.9 billion.

  • Sanofi's Non-Current Debt rose 1097.37% to $14.9 billion in Q2 2025 from the same period last year, while for Jun 2025 it was $14.9 billion, marking a year-over-year increase of 1097.37%. This contributed to the annual value of $12.6 billion for FY2024, which is 1881.25% down from last year.
  • Latest data reveals that Sanofi reported Non-Current Debt of $14.9 billion as of Q2 2025, which was up 1097.37% from $12.6 billion recorded in Q4 2024.
  • Sanofi's 5-year Non-Current Debt high stood at $21.6 billion for Q2 2021, and its period low was $12.6 billion during Q4 2024.
  • For the 5-year period, Sanofi's Non-Current Debt averaged around $16.1 billion, with its median value being $15.4 billion (2023).
  • As far as peak fluctuations go, Sanofi's Non-Current Debt plummeted by 2261.77% in 2022, and later soared by 1097.37% in 2025.
  • Quarter analysis of 5 years shows Sanofi's Non-Current Debt stood at $19.6 billion in 2021, then dropped by 22.62% to $15.2 billion in 2022, then grew by 1.84% to $15.4 billion in 2023, then decreased by 18.38% to $12.6 billion in 2024, then rose by 18.59% to $14.9 billion in 2025.
  • Its Non-Current Debt was $14.9 billion in Q2 2025, compared to $12.6 billion in Q4 2024 and $13.5 billion in Q2 2024.